Cargando…

Time course of conjunctival hyperemia induced by omidenepag isopropyl ophthalmic solution 0.002%: a pilot, comparative study versus ripasudil 0.4%

OBJECTIVE: We investigated the detailed time course of conjunctival hyperemia induced by omidenepag isopropyl ophthalmic solution 0.002% (omidenepag), a selective prostaglandin E2 receptor 2 agonist. METHODS AND ANALYSIS: We recruited 34 healthy subjects and administered omidenepag in the right eye...

Descripción completa

Detalles Bibliográficos
Autores principales: Terao, Etsuko, Nakakura, Shunsuke, Fujisawa, Yasuko, Nagata, Yuki, Ueda, Kanae, Kobayashi, Yui, Oogi, Satomi, Dote, Saki, Shiraishi, Miku, Tabuchi, Hitoshi, Yoneda, Tsuyoshi, Fukushima, Atsuki, Asaoka, Ryo, Kiuchi, Yoshiaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7398095/
https://www.ncbi.nlm.nih.gov/pubmed/32818152
http://dx.doi.org/10.1136/bmjophth-2020-000538
_version_ 1783565895705034752
author Terao, Etsuko
Nakakura, Shunsuke
Fujisawa, Yasuko
Nagata, Yuki
Ueda, Kanae
Kobayashi, Yui
Oogi, Satomi
Dote, Saki
Shiraishi, Miku
Tabuchi, Hitoshi
Yoneda, Tsuyoshi
Fukushima, Atsuki
Asaoka, Ryo
Kiuchi, Yoshiaki
author_facet Terao, Etsuko
Nakakura, Shunsuke
Fujisawa, Yasuko
Nagata, Yuki
Ueda, Kanae
Kobayashi, Yui
Oogi, Satomi
Dote, Saki
Shiraishi, Miku
Tabuchi, Hitoshi
Yoneda, Tsuyoshi
Fukushima, Atsuki
Asaoka, Ryo
Kiuchi, Yoshiaki
author_sort Terao, Etsuko
collection PubMed
description OBJECTIVE: We investigated the detailed time course of conjunctival hyperemia induced by omidenepag isopropyl ophthalmic solution 0.002% (omidenepag), a selective prostaglandin E2 receptor 2 agonist. METHODS AND ANALYSIS: We recruited 34 healthy subjects and administered omidenepag in the right eye and ripasudil 0.4% in the left eye. We evaluated conjunctival hyperemia using slit-lamp photography at baseline and after 15, 30, 60, 120, 180 and 360 min. The conjunctival hyperemia score was graded by three independent observers using a scale from 0 (none) to 3 (severe). We also evaluated conjunctival hyperemia by the pixel coverage of conjunctival blood vessels (per cent coverage) determined using a conjunctival hyperemia-analysing software. RESULTS: In omidenepag, the conjunctival hyperemia score and per cent coverage peaked at both 30 min (mean score±SD: 1.57±0.67 and 11.90%±3.66%, respectively) and then gradually decreased at 60 min (10.79%±3.32%) and 120 min (1.10±0.52) when they reached a level that was not significantly different from the baseline values. For ripasudil 0.4%, the peak time of the conjunctival hyperemia score and per cent coverage were both at 15 min (score: 2.42±0.54 and 15.26%±3.38%). The degree of conjunctival hyperemia was significantly higher for ripasudil 0.4% than that for omidenepag from 15 to 30 min in both the conjunctival hyperemia score and per cent coverage (p<0.007 by Bonferroni correction). CONCLUSION: Conjunctival hyperemia induced by omidenepag gradually peaks to moderate severity, though weaker compared with that induced by ripasudil 0.4%, and subsides relatively quickly.
format Online
Article
Text
id pubmed-7398095
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-73980952020-08-17 Time course of conjunctival hyperemia induced by omidenepag isopropyl ophthalmic solution 0.002%: a pilot, comparative study versus ripasudil 0.4% Terao, Etsuko Nakakura, Shunsuke Fujisawa, Yasuko Nagata, Yuki Ueda, Kanae Kobayashi, Yui Oogi, Satomi Dote, Saki Shiraishi, Miku Tabuchi, Hitoshi Yoneda, Tsuyoshi Fukushima, Atsuki Asaoka, Ryo Kiuchi, Yoshiaki BMJ Open Ophthalmol Original Research OBJECTIVE: We investigated the detailed time course of conjunctival hyperemia induced by omidenepag isopropyl ophthalmic solution 0.002% (omidenepag), a selective prostaglandin E2 receptor 2 agonist. METHODS AND ANALYSIS: We recruited 34 healthy subjects and administered omidenepag in the right eye and ripasudil 0.4% in the left eye. We evaluated conjunctival hyperemia using slit-lamp photography at baseline and after 15, 30, 60, 120, 180 and 360 min. The conjunctival hyperemia score was graded by three independent observers using a scale from 0 (none) to 3 (severe). We also evaluated conjunctival hyperemia by the pixel coverage of conjunctival blood vessels (per cent coverage) determined using a conjunctival hyperemia-analysing software. RESULTS: In omidenepag, the conjunctival hyperemia score and per cent coverage peaked at both 30 min (mean score±SD: 1.57±0.67 and 11.90%±3.66%, respectively) and then gradually decreased at 60 min (10.79%±3.32%) and 120 min (1.10±0.52) when they reached a level that was not significantly different from the baseline values. For ripasudil 0.4%, the peak time of the conjunctival hyperemia score and per cent coverage were both at 15 min (score: 2.42±0.54 and 15.26%±3.38%). The degree of conjunctival hyperemia was significantly higher for ripasudil 0.4% than that for omidenepag from 15 to 30 min in both the conjunctival hyperemia score and per cent coverage (p<0.007 by Bonferroni correction). CONCLUSION: Conjunctival hyperemia induced by omidenepag gradually peaks to moderate severity, though weaker compared with that induced by ripasudil 0.4%, and subsides relatively quickly. BMJ Publishing Group 2020-08-02 /pmc/articles/PMC7398095/ /pubmed/32818152 http://dx.doi.org/10.1136/bmjophth-2020-000538 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Original Research
Terao, Etsuko
Nakakura, Shunsuke
Fujisawa, Yasuko
Nagata, Yuki
Ueda, Kanae
Kobayashi, Yui
Oogi, Satomi
Dote, Saki
Shiraishi, Miku
Tabuchi, Hitoshi
Yoneda, Tsuyoshi
Fukushima, Atsuki
Asaoka, Ryo
Kiuchi, Yoshiaki
Time course of conjunctival hyperemia induced by omidenepag isopropyl ophthalmic solution 0.002%: a pilot, comparative study versus ripasudil 0.4%
title Time course of conjunctival hyperemia induced by omidenepag isopropyl ophthalmic solution 0.002%: a pilot, comparative study versus ripasudil 0.4%
title_full Time course of conjunctival hyperemia induced by omidenepag isopropyl ophthalmic solution 0.002%: a pilot, comparative study versus ripasudil 0.4%
title_fullStr Time course of conjunctival hyperemia induced by omidenepag isopropyl ophthalmic solution 0.002%: a pilot, comparative study versus ripasudil 0.4%
title_full_unstemmed Time course of conjunctival hyperemia induced by omidenepag isopropyl ophthalmic solution 0.002%: a pilot, comparative study versus ripasudil 0.4%
title_short Time course of conjunctival hyperemia induced by omidenepag isopropyl ophthalmic solution 0.002%: a pilot, comparative study versus ripasudil 0.4%
title_sort time course of conjunctival hyperemia induced by omidenepag isopropyl ophthalmic solution 0.002%: a pilot, comparative study versus ripasudil 0.4%
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7398095/
https://www.ncbi.nlm.nih.gov/pubmed/32818152
http://dx.doi.org/10.1136/bmjophth-2020-000538
work_keys_str_mv AT teraoetsuko timecourseofconjunctivalhyperemiainducedbyomidenepagisopropylophthalmicsolution0002apilotcomparativestudyversusripasudil04
AT nakakurashunsuke timecourseofconjunctivalhyperemiainducedbyomidenepagisopropylophthalmicsolution0002apilotcomparativestudyversusripasudil04
AT fujisawayasuko timecourseofconjunctivalhyperemiainducedbyomidenepagisopropylophthalmicsolution0002apilotcomparativestudyversusripasudil04
AT nagatayuki timecourseofconjunctivalhyperemiainducedbyomidenepagisopropylophthalmicsolution0002apilotcomparativestudyversusripasudil04
AT uedakanae timecourseofconjunctivalhyperemiainducedbyomidenepagisopropylophthalmicsolution0002apilotcomparativestudyversusripasudil04
AT kobayashiyui timecourseofconjunctivalhyperemiainducedbyomidenepagisopropylophthalmicsolution0002apilotcomparativestudyversusripasudil04
AT oogisatomi timecourseofconjunctivalhyperemiainducedbyomidenepagisopropylophthalmicsolution0002apilotcomparativestudyversusripasudil04
AT dotesaki timecourseofconjunctivalhyperemiainducedbyomidenepagisopropylophthalmicsolution0002apilotcomparativestudyversusripasudil04
AT shiraishimiku timecourseofconjunctivalhyperemiainducedbyomidenepagisopropylophthalmicsolution0002apilotcomparativestudyversusripasudil04
AT tabuchihitoshi timecourseofconjunctivalhyperemiainducedbyomidenepagisopropylophthalmicsolution0002apilotcomparativestudyversusripasudil04
AT yonedatsuyoshi timecourseofconjunctivalhyperemiainducedbyomidenepagisopropylophthalmicsolution0002apilotcomparativestudyversusripasudil04
AT fukushimaatsuki timecourseofconjunctivalhyperemiainducedbyomidenepagisopropylophthalmicsolution0002apilotcomparativestudyversusripasudil04
AT asaokaryo timecourseofconjunctivalhyperemiainducedbyomidenepagisopropylophthalmicsolution0002apilotcomparativestudyversusripasudil04
AT kiuchiyoshiaki timecourseofconjunctivalhyperemiainducedbyomidenepagisopropylophthalmicsolution0002apilotcomparativestudyversusripasudil04